ACA
DFTX

American Capital Advisory’s Definium Therapeutics DFTX Stock Holding History

American Capital Advisory’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33
Closed -$121 – 504
2024
Q2 		$121 Hold
33
– – ﹤0.01% 413
2024
Q1 		$105 Hold
33
– – ﹤0.01% 435
2023
Q4 		$121 Buy
+33
New +$99 ﹤0.01% 413

Other funds holding DFTX

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Capital Advisory's DFTX Position: Q3 2024 in Review

American Capital Advisory sold out of Definium Therapeutics (DFTX) in Q3 2024, closing a stake of 33 shares — an estimated $121 sold.

American Capital Advisory first reported a position in DFTX in Q4 2023 and held it in 3 quarters. The position peaked at $121 in Q2 2024. 157 funds tracked by Wall St. Rank hold DFTX as of Q3 2024.

  • American Capital Advisory reported no remaining Definium Therapeutics position as of Q3 2024 after selling out during the quarter.
  • American Capital Advisory sold 33 Definium Therapeutics shares in Q3 2024, an estimated $121.
  • American Capital Advisory first reported a position in Definium Therapeutics in Q4 2023 and held it in 3 quarters.
  • American Capital Advisory's Definium Therapeutics position peaked at $121 in Q2 2024.
  • 157 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2024.

Based on American Capital Advisory's 13F filing for Q3 2024, filed 30 Oct 2024.